Ischemic heart disease is one of the most dreaded clinical conditions since the mortality and morbidity rates associated with it are very high. It is a medical emergency, and thus needs immediate specific and supportive care, as mandated. Management of ischemic heart disease involves two modalities...
survival following treatment has improved in the last two decades, the morbidity and mortality of MI still remain high. LEADINGLEADING CAUSESCAUSES OFOF MORTALITYMORTALITY ININ WHOWHO REPORTREPORT The mortality of ischaemic heart disease is ranked first among ...
The availability of thesenewer drugs expands the therapeutic potential of medical treatment to even awider population with stable IHD. Revascularization in patients with stableischemic heart disease has never been shown to reduce hard endpoints (death ormyocardial infarction) in randomized clinical trials...
In developing a treatment plan for elderly patients with ischemic heart disease, it is important to appreciate that the pathophysiologic process and aging influence the type of response produced by various drugs. The aging process also alters the way drugs are absorbed, distributed, and eliminated. ...
Stem cell therapy for ischemic heart disease: Beginning or end of the road? Despite improvements in emergency treatment, myocardial infarction is often the beginning of a downward spiral leading to congestive heart failure. Other t... C Stamm,A Liebold,G Steinhoff,... - International Workshop ...
BRILINTA® (ticagrelor) is an oral prescription indicated for treatment of acute ischemic stroke, coronary artery disease and acute coronary syndrome.
BRILINTA® (ticagrelor) is an oral prescription indicated for treatment of acute ischemic stroke, coronary artery disease and acute coronary syndrome.
The natural course of ischemic heart disease was followed up in 240 patients in periods of 1 to 7 years (average follow-up period 3 years). In all patients the character of affection of the coronary arteries was verified by angiography. The coronary arteries were normal or had mild changes ...
BRILINTA® (ticagrelor) is an oral prescription indicated for treatment of acute ischemic stroke, coronary artery disease and acute coronary syndrome.
with ischemic heart disease (IHD) (which was presented by angina pectoris, class I-III, or myocardial infarction history) were included into the first group (G1). Other 54 patients (38 men, 16 women; aged 64,1±10,2 y.o.) with IHD associated with obliterative atherosclerosis of lower ...